Scheduling Infusion & Delivery Services

Infusion coordination is handled by dedicated Prolastin Direct® Patient Services care coordinators. They can locate appropriate sites for infusions and coordinate all details, including scheduling infusion nurses, for you. All infusion nurses have access to specialized PROLASTIN-C training.

Pharmacy services with Prolastin Direct® Patient Services are handled by a staff of dedicated pharmacists at Centric Health Resources who are on call 24 hours a day, every day. Services are customized for your needs, just as they are for each patient with Alpha-1.

Reliable delivery directly to any location of care is another service of Prolastin Direct® Patient Services. Based on the dosage schedule prescribed by your doctor, PROLASTIN-C is shipped automatically on a regular basis to the location where you’ll receive your infusions. This ensures that you have PROLASTIN-C when and where you need it.

Home infusion services from Prolastin Direct® Patient Services enable scheduling flexibility and convenience for you and your family. This service provides home infusion by Alpha-1–certified nurses, who are provided through a national network of infusion nurses. Of course, we can also coordinate infusions in more traditional places, such as clinics and hospitals, if you and your doctor decide that is best.

Health management services from Prolastin Direct® Patient Services include education and supportive follow-up from AlphaNet Coordinators. All coordinators are patients with Alpha-1 themselves who have been specially trained to help other Alpha-1 patients like you.

Find a Clinical Resource Center near you

There are over 50 Clinical Resource Centers in North America that specialize in patient care and education for patients with Alpha-1. Find the nearest Clinical Resource Centers by visiting the Alpha-1 Foundation Web site.

next: Network with Others with Alpha-1 >

Important Safety Information
Prolastin-C, Alpha1-Proteinase Inhibitor (Human) is for adults who have emphysema caused by inherited alpha1-antitrypsin deficiency. The effect of therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Prolastin-C may contain trace amounts of IgA. IgA deficient patients with antibodies against IgA should not receive Prolastin-C due to the risk of hypersensitivity.

The most common side effects during clinical trials with Prolastin-C were chills, a general feeling of being unwell, headache, rash, hot flush, and itching.

Prolastin-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying Prolastin-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References
  1. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha 1 antitrypsin deficiency. COPD. 2009;6(1):31-40.